Table 1 The characteristics of participants.
Clinical Values | Total (n = 272) | Training Set (n = 217) | Validation Set (n = 55) |
|---|---|---|---|
Age, median(range), y | 59(33–84) | 59(33–84) | 60(33–84) |
Gender | |||
Male, no. (%) | 167(61.4%) | 135(62.21%) | 32(58.18%) |
Female, no. (%) | 105(38.6%) | 82(37.79%) | 23(41.82%) |
Eye | |||
Right, no. (%) | 153(56.25%) | 122(56.22%) | 31(56.36%) |
Left, no. (%) | 119(43.75%) | 95(43.78%) | 24(43.64%) |
IOP, mean (SD) | 16.283(3.801) | 16.456(4.081) | 15.600(2.298) |
Anti-VEGF drugs | |||
Ranibizumab, no. (%) | 60(22.06%) | 50(23.04%) | 10(18.18%) |
Conbercept, no. (%) | 182(66.91%) | 141(64.98%) | 41(74.55%) |
Aflibercept, no. (%) | 30(11.03%) | 26(11.98%) | 4(7.27%) |
Follow-up time, mean (SD), d | 31.658(20.472) | 32.005(20.300) | 30.291(21.272) |
Pretherapy | |||
BCVA, median (25%,75%) | 0.699(0.398,1) | 0.699(0.398,1) | 0.699(0.460,1) |
CST, mean (SD), µm | 369.540(158.233) | 362.917(149.169) | 395.672 ± 189.139 |
CV, mean (SD), mm3 | 14.454(5.480) | 14.207(5.394) | 15.429 ± 5.756 |
CAT, mean (SD), µm | 369.438(74.866) | 366.259(74.280) | 381.977 ± 76.535 |
Post-treatment | |||
BCVA, median (25%,75%) | 0.699(0.301,1) | 0.699(0.301,1) | 0.602(0.398,0.921) |
CST, mean (SD), µm | 309.648(124.630) | 311.227(120.060) | 303.416(142.278) |
CV, mean (SD), mm3 | 12.982(3.012) | 12.862(2.944) | 13.460(3.248) |
CAT, mean (SD), µm | 350.625(66.037) | 349.923(63.827) | 353.395(74.697) |
Prognosis (improved) | |||
BCVA, no. (%) | 131(48.16%) | 99(45.62%) | 32(58.18%) |
CST, no. (%) | 184(67.65%) | 146(67.28%) | 38(69.09%) |
CV, no. (%) | 193(70.96%) | 150(69.12%) | 43(78.18%) |
CAT, no. (%) | 191(70.22%) | 149(68.66%) | 42(76.36%) |
